VLife Sciences Technologies (VLife), a Pune-based
computer-aided drug and molecular discovery technologies provider, and
Computational Research Laboratories (CRL), a wholly-owned subsidiary of
Tata Sons and developer of commercial supercomputing facility ‘eka’,
based in Pune, have partnered to offer VLife’s GRIP docking technology
on CRL’s high performance computing platform.
This new offering is expected to reduce the time required to conduct
protein – ligand docking studies. Structure-based drug design approach
has traditionally been affected by limitations due to either slow or
inaccurate docking activity. Researchers rarely could access a solution
that was fast while being accurate. With the combination of VLife’s
innovative GRIP technology and the computational power of CRL’s
supercomputer ‘eka’, researchers can improve productivity from their
structure-based design efforts. With this joint offering, VLife and CRL
have reinforced their commitment to address the scientific and
technological challenges in the computational discovery domain on the
basis of their core strengths.
Supreet Deshpande, director, VLife Sciences Technologies, said, “Our
alliance with CRL to provide accurate yet rapid docking service powered
by our GRIP docking technology demonstrates VLife’s commitment to
innovators in the area of life sciences in general and pharmaceuticals
“We are delighted to tie up with VLife to bring to scientists the
combined power of a high performance computational cluster and a smart
and accurate docking technology,” said Dr Vipin Chaudhary, CEO, CRL.
accredited with ISO 13485:2003 certification
RMS Regrow, the cell therapy and cord blood banking service provider in
India, has been accredited with ISO 13485:2003 certification. The
company has received this certification for its therapies, Chondron and
Ossron; and cord blood banking service, BabyCell.
ISO 13485:2003 specifies requirements for a quality management system
where an organization needs to demonstrate its ability to provide
medical devices and related services that consistently meet customer
requirements and regulatory requirements applicable to medical devices
and related services. The primary objective of ISO 13485:2003 is to
facilitate harmonized medical device regulatory requirements for
quality management systems.
Talking about the ISO certification Dr Vinayak V Kedage, lab director,
RMS Regrow, said, “We are delighted to receive this certification. RMS
has been following stringent quality management procedures in its
business operations. The ISO 13485:2003 will ensure that our medical
devices and related services will now be in compliance with global
standards. This certification will further build trust and confidence
of RMS amongst its customers and associates.”
Clinpharm to set up operations in Asia Pacific region
After establishing its presence in the US, Western and Eastern Europe,
Indian CRO, SIRO Clinpharm is planning to expand its full-scale
operations in the Asian Pacific region.
“As far as clinical research is concerned, Asia Pacific is a huge
market. Presently, we do not have any full-scale operations to conduct
phase I-IV clinical trials. So, we are actively looking at setting up a
base there,” said a company source to BioSpectrum
Details of the investments both in terms of infrastructure, manpower
and finances are yet to be disclosed. Dr Chetan Tamhankar, CEO, SIRO
Clinpharm, earlier told BioSpectrum that their strategy team has
chalked out plans for North America and South East Asia in order to
achieve a turnover of Rs 500 crore in the coming months. He also
confirmed that the CRO’s investors will opt for an exit strategy
through an IPO route by 2011. SIRO presently has three investors that
includes Kotak Private Equity, 3i and the promoter, the Daftarys.
SIRO Clinpharm has already made inroads into the APAC region
through a number of strategic alliances. In April 2010, it announced
its alliance with Virginia CRO (VCRO), a Taiwan-based CRO. VCRO has
extensive network in the Asia Pacific regions including Japan, China,
Singapore and Hong Kong. The pact with VCRO enables SIRO’s clients
access to Taiwan’s clinical research market. The clinical trials market
in Taiwan is an attractive destination for global pharma-biotech firms.
In February 2010, SIRO also announced another partnership with a
Korea-based CRO, DreamCIS.